Ashish Kacholia recent bets

Morgan Stanley recent bets

Recent Big Buys

Hasn't fared well - amongst the low performers

Performance

Can be considered moderately valued vs the market

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Seems to be overvalued vs the market average

Price return has been average, nothing exciting

Average profitability - not good, not bad

Top deal-making stocks

Most insider traded stocks

Leading investors

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

The Nifty Pharma index closed 1.04 per cent at 21972.70.

Stock market update: Nifty Pharma index 1.04%

The Nifty Pharma index was trading 0.93 per cent at 21997.80.

Stock market update: Nifty Pharma index 0.93% in an upbeat market

The Nifty Pharma index closed 1.37 per cent at 22203.90.

Stock market update: Nifty Pharma index 1.37%

The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharma firms are also big beneficiaries when the rupee weakens. To put it in perspective: Among India’s top pharma companies, there are some that have more than 57% of their sales coming from exports. In one case, export contribution is as high as 88%. So, a decline in the rupee increases the probability of their margins moving higher in the coming quarters. Another plus: It is one sector where US President-elect Donald Trump is unlikely to create problems. He cannot afford to mess with an already messed-up US healthcare system.

Decline in rupee: Besides IT, there are other winners as well; 9 pharma stocks with an upside potential of up to 40%

The Nifty Pharma index was trading 0.06 per cent at 21916.55.

Stock market update: Nifty Pharma index 0.06% in an upbeat market

Axis Securities gives an overweight call on Aurobindo Pharma with a target price of Rs 1,500. The current market price is Rs 1173.85. The company is a large cap firm in the pharmaceutical sector with a market cap of Rs 67529.80 crore. Key products include pharmaceuticals and export incentives. The company reported a net profit of Rs 816.

Overweight on Aurobindo Pharma, target price Rs 1,500: Axis Securities

The Nifty Pharma index closed 2.13 per cent at 21903.35.

Stock market update: Nifty Pharma index 2.13%

The Nifty Pharma index was trading 1.31 per cent at 22088.10.

Stock market update: Nifty Pharma index 1.31% in a weak market

The Pharma sector outperformed in 2024, gaining 29%, driven by resilience to macro challenges, US FDA resolutions, and innovation in complex products. Valuations at 29 times forward earnings reflect optimism but pose risks given limited margin expansion and looming product cliffs like gRevlimid in 2026. While companies like Cipla and Lupin have strong pipelines, and Dr. Reddy’s and Zydus are diversifying, high valuations and structural challenges call for tempered expectations.

Banking on Pharma

JM Financial predicts 5.8% YoY profit growth in 3QFY25, driven by IT services and pharmaceuticals, despite challenges in BFSI.

IT services, Pharma sector PAT to grow by 5.8% in Q3FY25: JM Financial

Zydus’ expanding product pipeline and strong fundamentals make it a compelling play in the pharmaceutical sector, the brokerage said.

Zydus Lifesciences Gets Nomura’s ‘Buy’ Upgrade On Earnings Growth, Currency Movement

The ETF tracks Nifty Pharma Index which is designed to reflect the behavior and performance of the pharmaceutical sector in India.